

Seat No.: \_\_\_\_\_

Enrolment No. \_\_\_\_\_

**GUJARAT TECHNOLOGICAL UNIVERSITY**  
**B.Pharm- SEMESTER-VII • EXAMINATION – WINTER -2020****Subject Code: 2270001****Date:01/01/2021****Subject Name: Dosage Form Design-I****Time: 10:30AM To 12:30PM****Total Marks: 54****Instructions:**

1. Attempt any **THREE** questions from Q-1 to Q-6.
2. Q.7 is compulsory to attempt.
3. Make suitable assumptions wherever necessary.
4. Figures to the right indicate full marks.

- Q.1** (a) What is Preformulation? Discuss the significance of particle size and shape in formulation. **06**  
(b) Explain the role of polymorphism and crystallinity in Preformulation. Enlist the methods to identify polymorphism. **05**  
(c) Enlist the chemical properties observed during preformulation study. Explain oxidation and reduction in detail. **05**
- Q.2** (a) Classify the polymers. Discuss in brief about polymer properties. **06**  
(b) Write a short note on "Plasma Protein Binding". **05**  
(c) Write a short note on Natural Gums. **05**
- Q.3** (a) Explain various methods used for enhancement of bioavailability. **06**  
(b) Explain the role of Biopharmaceutics in formulation development. **05**  
(c) Discuss the regulatory requirements for conduction of bio-equivalence Studies. **05**
- Q.4** (a) Write a note on factors affecting drug absorption. **06**  
(b) Define i) Bioavailability ii) Cmax iii) tmax iv) Overage v) Mean Kinetic Temperature **05**  
(c) What is IVIVC? Describe In-vitro -In-vivo correlations levels. **05**
- Q.5** (a) What is BCS classification? How does it affect development of dosage form? **06**  
(b) Discuss Matrixing and Bracketing Techniques. **05**  
(c) Effect of pKa and pH on absorption parameter. **05**
- Q.6** (a) Define Half-life and Self life. Discuss about international climatic zones as per ICH guideline **06**  
(b) Discuss the factors affecting stability of pharmaceutical formulation. **05**  
(c) Discuss the effect of containers and closures on stability of pharmaceuticals. **05**
- Q.7** (a) Discuss stability testing of new drug substances and products as per ICH guideline. **06**
- OR**
- (a) Write a note on volume of distribution. **06**
- OR**
- (a) Storage conditions for stability testing as per ICH guidelines. **06**

\*\*\*\*\*